Advertisement

Cancer gene therapy

  • Donald J. Buchsbaum
  • C. Ryan Miller
  • Parameshwar J. Mahasreshti
  • David T. Curiel
Chapter

Abstract

Cancer is the product of a multistep process involving an accumulation of genetic alterations in somatic cells [268]. Advances in the understanding of the molecular basis of neoplasia and host—tumor relationships have resulted in new cancer therapy strategies with translation into clinical trials. Gene therapy has emerged as a treatment strategy which relies on the introduction of genetic material to cure, slow the progression, or possibly even prevent a variety of diseases including genetic, infectious (HIV in particular), cardiovascular, and arthritic diseases [12, 83]. Gene therapy has shown potential for the treatment of cancer. A number of cancer gene therapy approaches have been developed based on direct correction of genetic lesions. These ‘mutation compensation’ approaches, designed to correct the molecular lesions underlying neoplastic transformation and progression, have demonstrated efficacy in the context of in-vitro and preclinical model systems. Delivery of therapeutic genes to every cancer cell is beyond the capabilities of current vectors. The efficiency and accuracy of gene delivery remain the most significant barriers to the success of cancer gene therapy [262]. However, preclinical studies have demonstrated approaches that may have promise in the clinical setting. The approaches that have been explored include genetic immunopotentiation with cytokine gene transfer and tumor cell vaccination, molecular chemotherapy with prodrug activation by suicide genes or an increase in tumor cell sensitivity to chemotherapy or radiation therapy, protection of bone marrow cells from the toxic effects of chemotherapeutic drugs, inhibition of activated oncogenes by antisense treatment, transfer of tumor suppressor genes, and pro-apoptotic gene therapy. Each of these approaches have been translated into clinical cancer therapy trials [43, 83].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gene therapy clinical trials database. http://www.wiley. co.uk/wileychi/genmed/clinicalGoogle Scholar
  2. 2.
    Adachi Y, Reynolds PN, Yamamoto M et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001; 61: 7882–88.PubMedGoogle Scholar
  3. 3.
    Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000; 2: 148–64.PubMedGoogle Scholar
  4. 4.
    Aghi M, Kramm CM, Breakefield XO. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999; 91: 1233–41.PubMedGoogle Scholar
  5. 5.
    Aghi M, Kramm CM, Chou T-C, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90: 370–80.PubMedGoogle Scholar
  6. 6.
    Aguilar–Cordova E, Ayala G, Miles BJ. 363–1999–12 Phase I Study of the Replication–Competent, E1B–Attenuated Adenovirus with a CD/HSV–1 TK Fusion Gene and the Oral Administration of Valaciclovir in Adults with Penile Cancer. Vol. 2002: National Institutes of Health Office of Biotechnology Activities Human Gene Transfer Clinical Trials Database, 1999.Google Scholar
  7. 7.
    Alemany R, Balague~ C, Curiel DT. Replicative adenoviruses for cancer therapy. Nature Biotech 2000; 18: 723–7.Google Scholar
  8. 8.
    Allay JA, Dumenco LL, Koc ON, Liu L, Gerson SL. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood 1995; 85: 3342–51.PubMedGoogle Scholar
  9. 9.
    Alvarez RD, Barnes MN, Gomez-Navarro J et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial. Clin Cancer Res 2000; 6: 3081–7.PubMedGoogle Scholar
  10. 10.
    Alvarez RD, Gomez-Navarro J, Wang Metal. Adenoviralmediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2: 524–30.PubMedGoogle Scholar
  11. 11.
    Anderson LM, Krotz S, Weitzman SA, and Thimmapaya B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther 2000; 7: 845–52.PubMedGoogle Scholar
  12. 12.
    Anderson WF. Human gene therapy. Nature 1998; 392: 25–30.PubMedGoogle Scholar
  13. 13.
    Ansardi DC, Porter DC, Jackson CA, Gillespie GY, and Morrow CD. RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins. Cancer Res 2001; 61: 8470–9.PubMedGoogle Scholar
  14. 14.
    Anwer K, Meaney C, Kao Get al. Cationic lipid-based delivery system for systemic cancer gene therapy. Cancer Gene Ther 2000; 7: 1156–64.PubMedGoogle Scholar
  15. 15.
    Arafat WO, Gómez-Navarro J, Xiang J et al. An adenovirus encoding proapoptotic bax induces apoptosis and enhances the radiation effect in human ovarian cancer. Mol Ther 2000; 1: 545–54.PubMedGoogle Scholar
  16. 16.
    Bacchetti S, Graham FL. Transfer of the gene for thymidine kinase to thymidine kinase-deficient human cells by purified herpes simplex viral DNA. Proc Natl Acad Sci USA 1977; 74: 1590–4.PubMedGoogle Scholar
  17. 17.
    Bagshawe KD. Cancer drug targeting. Clin Radiol 1985; 36: 545–51.PubMedGoogle Scholar
  18. 18.
    Bagshawe KD, Springer CJ, Searle F et al. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988; 58: 700–3.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Bartlett JS. Prospects for the development of targeted adeno-associated virus (AAV) vector systems. Tumor Targeting 1999; 4: 143–9.Google Scholar
  20. 20.
    Baselga J. New horizons: gene therapy for cancer. Anti-Cancer Drugs 1999; 10 (Suppl. 1): S39 - S42.PubMedGoogle Scholar
  21. 21.
    -2000–01 A Gene Therapy Based Myeloprotection Strategy Using a Mutant Dihydrofolate Reductase - Cytidine Deaminase Fusion Gene for the Treatment of Refractory or Relapsed Non-Hodgkin’s Lymphoma. Vol. 2002: National Institutes of Health Office of Biotechnology Activities Human Gene Transfer Clinical Trials Database, 2001.Google Scholar
  22. 22.
    Bichsel VE, Liotta LA, Petricoin EF, 3rd. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 2001; 7: 69–78.PubMedGoogle Scholar
  23. 23.
    Blackstock AW, Lightfoot H, Case LD et al. Tumor uptake and elimination of 2’,2’-difluoro-2’-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 2001; 7: 3263–3268.PubMedGoogle Scholar
  24. 24.
    Boland A, Ricard M, Opolon P et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484–92.PubMedGoogle Scholar
  25. 25.
    Borrelli E, Heyman R, Hsi M, Evans RM. Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA 1988; 85: 7572–6.PubMedGoogle Scholar
  26. 26.
    Botella-Estrada R, Malet G, Revert Fetal. Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin. Cancer Gene Ther 2001; 8: 278–84.PubMedGoogle Scholar
  27. 27.
    Brade AM, Ngo D, Szmitko P, Li P-X, Liu F-F, Klamut HJ. Heat-directed gene targeting of adenoviral vectors to tumor cells. Cancer Gene Ther 2000; 7: 1566–74.PubMedGoogle Scholar
  28. 28.
    Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995; 31A: 2362–70.Google Scholar
  29. 29.
    Brower V. Tumor angiogenesis-new drugs on the block. Nat Biotechnol 1999; 17: 963–8.PubMedGoogle Scholar
  30. 30.
    Buchschacher GL Jr, Wong-Staal F. Development of lenti-viral vectors for gene therapy for human diseases. Blood 2000; 95: 2499–504.PubMedGoogle Scholar
  31. 31.
    Bzowska A, Kulikowska E, Shugar D. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Ther 2000; 88: 349–425.PubMedGoogle Scholar
  32. 32.
    Carter P. Improving the efficacy of antibody-based cancer therapies. Nature Rev Cancer 2001; 1: 118–29.Google Scholar
  33. 33.
    Channon KM, George SE. Improved adenoviral vectors: cautious optimism for gene therapy. Q J Med 1997; 90: 105–109.Google Scholar
  34. 34.
    Chaudhuri TR, Rogers BE, Buchsbaum DJ, Mountz JM, Zinn KR. A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts. Gynecol Oncol2001; 83: 432–8.Google Scholar
  35. 35.
    Chen CT, Lin J, Li Q et al. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther 2000; 11: 1983–96.PubMedGoogle Scholar
  36. 36.
    Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995; 55: 581–9.PubMedGoogle Scholar
  37. 37.
    Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by co-expression of the P450 reductase gene. Cancer Res 1997; 57: 4830–7.PubMedGoogle Scholar
  38. 38.
    Cheng WF, Hung CF, Chai CY et al. Tumor specific immunity and antiangiogensis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. Clin Invest 2001; 5: 669–78.Google Scholar
  39. 39.
    Chiang C-S, Hong J-H, Wu YC, McBride WH, Dougherty GJ. Combining radiation therapy with interleukin-3 gene immunotherapy. Cancer Gene Ther 2000; 7: 1172–8.PubMedGoogle Scholar
  40. 40.
    Chmura SJ, Advani SJ, Kufe DW, Weichselbaum RR. Strategies for enhancing viral-based gene therapy using ionizing radiation. Radiat Oncol Investig 1999; 7: 261–9.PubMedGoogle Scholar
  41. 41.
    Chung-Faye G, Palmer D, Anderson D et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 2001; 7: 2662–8.PubMedGoogle Scholar
  42. 42.
    Chung-Faye GA, Chen MJ, Green NK et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001; 8: 1547–54.PubMedGoogle Scholar
  43. 43.
    Clayman GL. The current status of gene therapy. Semin Oncol 2000; 27: 39–43.PubMedGoogle Scholar
  44. 44.
    Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999; 5: 1715–22.PubMedGoogle Scholar
  45. 45.
    Cline MJ, Stang H, Mercola K, Morse L, Ruprecht R, Brown J, Salser W. Gene transfer in intact animals. Nature 1980; 284: 422–5.PubMedGoogle Scholar
  46. 46.
    Cohen H, Levy RJ, Gao J et al. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 2000; 7: 1896–905.PubMedGoogle Scholar
  47. 47.
    Colvin OM. An overview of cyclophosphamide development and clinical applications. Curr Pharm Des 1999; 5: 555–60.PubMedGoogle Scholar
  48. 48.
    Cowan KH, Moscow JA, Huang H et al. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retro-virus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 1999; 5: 1619–28.PubMedGoogle Scholar
  49. 49.
    Crystal RG, Harvey BG, Wisnivesky JP et al. Analysis of risk factors for local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther 2002; 13: 65–100.PubMedGoogle Scholar
  50. 50.
    Crystal RG, Hirschowitz E, Lieberman M et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997; 8: 985–1001.Google Scholar
  51. 51.
    Culver KW, Ram Z, Walbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550–2.PubMedGoogle Scholar
  52. 52.
    -2001–04 A Phase I Trial of Genetically Modified Salmonella typhimurium Expressing Cytosine Deaminase (TAPET-CD, VNP20029) Administered by Intra -Tumoral Injection in Combination with 5- fluorocytosine for Patients with Advanced or Metastatic Cancer. Vol. 2002: National Institutes of Health Office of Biotechnology Activities Human Gene Transfer Clinical Trials Database, 2001.Google Scholar
  53. 53.
    Curiel DT. Strategies to adapt adenoviral vectors for targeted delivery. Ann NY Acad Sci 1999; 886: 158–71.PubMedGoogle Scholar
  54. 54.
    Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 2000; 6: 3395–9.PubMedGoogle Scholar
  55. 55.
    Dang CV, Gerson SL, Litwak M, and Padarathsingh M. Gene therapy and translational cancer research. Clin Cancer Res 1999; 5: 471–4.PubMedGoogle Scholar
  56. 56.
    Danks MK, Morton CL, Pawlik CA, Potter PM. Over-expression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res 1998; 58: 20–2.PubMedGoogle Scholar
  57. 57.
    Davidoff AM, Ng CY, Brown P et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 2001; 7: 2870–9.PubMedGoogle Scholar
  58. 58.
    de Gast GC, Gallee MPW, Spits H et al. Immunological, pathological, and long-term clinical data of vaccination with autologous granulocoyte-macrophage colony-stimulating factor-transduced tumor cells in metastatic melanoma. Cancer Gene Ther 2000; 7: 1204.Google Scholar
  59. 59.
    Deshane J, Cabrera G, Grim JE et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 1995; 59: 8–14.PubMedGoogle Scholar
  60. 60.
    Deshane J, Grim J, Loechel S, Siegal GP, Alvarez RD, Curiel DT. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther 1996; 3: 89–98.PubMedGoogle Scholar
  61. 61.
    Diaz RM, Bateman A, Emiliusen L et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther 2000; 7: 1656–63.PubMedGoogle Scholar
  62. 62.
    Dorigo O, Turla ST, Lebedeva S, Gjerset RA. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J Neurosurg 1998; 88: 535–40.PubMedGoogle Scholar
  63. 63.
    Dranoff G. Cancer gene therapy: connecting basic research with clinical inquiry. J Clin Oncol 1998; 16: 2548–56.PubMedGoogle Scholar
  64. 64.
    Dropulic B. Lentivirus in the clinic. Mol Ther 2001; 4: 511–12.PubMedGoogle Scholar
  65. 65.
    Eck SL. The prospects for gene therapy. Hosp Pract 1999; 34: 67–75.Google Scholar
  66. 66.
    Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med 1982; 73: 7–13.PubMedGoogle Scholar
  67. 67.
    Eliopoulos N, Cournoyer D, Momparler RL. Drug resistance to 5-aza-2’-deoxycytidine, 2’,2’-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 1998; 42: 373–8.PubMedGoogle Scholar
  68. 68.
    Erbs P, Regulier E, Kintz J et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813–22.PubMedGoogle Scholar
  69. 69.
    Evoy D, Hirschowitz EA, Naama HA et al. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res 1997; 69: 226–31.PubMedGoogle Scholar
  70. 70.
    Fahraeus R, Fischer P, Krausz E, Lane DP. New approaches to cancer therapies. J Pathol 1999; 187: 138–46.PubMedGoogle Scholar
  71. 71.
    Feldman AL, Friedl J, Lans TE et al. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002; 99: 149–153.PubMedGoogle Scholar
  72. 72.
    Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer 2000; 89: 1181–94.PubMedGoogle Scholar
  73. 73.
    Finn OJ, Lotze MT. Cellular immunity and immunotherapy of cancer. Clin Cancer Res (Suppl) 2001; 7: 759s - 989s.Google Scholar
  74. 74.
    -2000–10 Phase I Study of Intraprostatic Administration of a Replication-Competent, Oncolytic Adenovirus Using Various Vector formulations to Patients with Localized Prostate Cancer Prior to Radical Prostatectomy. Vol. 2002: National Institutes of Health Office of Biotechnology Activities Human Gene Transfer Clinical Trials Database, 2000.Google Scholar
  75. 75.
    Freytag SO, Kim JH. 464–2001–04 Phase I Study of Combined Suicide Gene Therapy and Radiation Therapy for Locally Advanced Carcinoma of the Prostate. Vol. 2002: National Institutes of Health Office of Biotechnology Activities Human Gene Transfer Clinical Trials Database, 2001.Google Scholar
  76. 76.
    Friedlos F, Davies L, Scanlon I et al. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res 2002; 62: 1724–9.PubMedGoogle Scholar
  77. 77.
    Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther 2000; 7: 1738–43.Google Scholar
  78. 78.
    Galanis E, Hersh EM, Stopeck AT et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 1999; 17: 3313–23.PubMedGoogle Scholar
  79. 79.
    Gambhir SS, Herschman HR, Cherry SR et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2000; 2: 118–38.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Gill RD, Cussac C, Souhami RL, Laval F. Increased resistance to N,N’,N“-triethylenethiophosphoramide (thiotepa) in cells expressing the Escherichia coli formamidopyrimidine-DNA glycosylase. Cancer Res 1996; 56: 3721–4.PubMedGoogle Scholar
  81. 81.
    Gomez-Navarro J, Arafat W, Xiang J. Gene therapy for carcinoma of the breast. Pro-apoptotic gene therapy. Breast Cancer Res 2000; 2: 32–44.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Gomez-Navarro J, Curiel DT. Conditionally replicative adenoviral vectors for cancer gene therapy. Lancet Oncol 2000; 1: 148–58.PubMedGoogle Scholar
  83. 83.
    Gomez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer. Eur J Cancer 1999; 35: 867–85.PubMedGoogle Scholar
  84. 84.
    Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev Cancer 2002; 2: 48–58.Google Scholar
  85. 85.
    Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187: 22–36.PubMedGoogle Scholar
  86. 86.
    Greco O, Folkes LK, Wardman P, Tozer GM, Dachs GU. Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3- acetic acid. Cancer Gene Ther 2000; 7: 1414–20.PubMedGoogle Scholar
  87. 87.
    Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000; 26: 269–86.PubMedGoogle Scholar
  88. 88.
    Greenbaum M, Letourneau S, Assar H, Schecter RL, Batist G, Cournoyer D. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH 3T3 mouse fibroblasts. Cancer Res 1994; 54: 4442–7.PubMedGoogle Scholar
  89. 89.
    Grifman M, Trepel M, Speece P et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3: 964–75.PubMedGoogle Scholar
  90. 90.
    Grill J, van Beusechem VW, Van Der Valk Petal. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res 2001; 7: 641–50.PubMedGoogle Scholar
  91. 91.
    Griscelli F, Li H, Cheong C et al. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci USA 2000; 97: 6698–703.PubMedGoogle Scholar
  92. 92.
    Grochow LB. Covalent DNA-binding agents. In: Perry MC (ed.) The Chemotherapy Source Book. Philadelphia: Lippincott Williams and Wilkins, 2001: 192–9.Google Scholar
  93. 93.
    Grove JI, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ. Virus-directed enzyme prodrug therapy using CB1954. Anticancer Drug Des 1999; 14: 461–72.PubMedGoogle Scholar
  94. 94.
    Gutheil JC, Finucane DM. Antimetabolites. In: Perry MC, ed. The Chemotherapy Source Book. Philadelphia: Lippincott Williams and Wilkins, 2001: 289–304.Google Scholar
  95. 95.
    Gyorffy S, Palmer K, Podor TJ, Hitt M, Gauldie J. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J Immunol2001; 166: 6212–17.Google Scholar
  96. 96.
    Haisma HJ, van Beusechem W, Curiel DT, Pinedo HM, Gerritsen WR. Targeted enzymes for molecular chemotherapy. Cancer Gene Ther 2000; 7: 1208.Google Scholar
  97. 97.
    Hamstra DA, Page M, Maybaum J, Rehemtulla A. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexatealpha-peptide prodrugs. Cancer Res 2000; 60: 657–65.PubMedGoogle Scholar
  98. 98.
    Hamstra DA, Rehemtulla A. Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum Gene Ther 1999; 10: 235–48.PubMedGoogle Scholar
  99. 99.
    Hamstra DA, Rice DJ, Fahmy S, Ross BD, Rehemtulla A. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther 1999; 10: 1993–2003.PubMedGoogle Scholar
  100. 100.
    Han S-o, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther 2000; 2: 302–17.Google Scholar
  101. 101.
    Hapke DM, Stegmann AP, Mitchell BS. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 1996; 56: 2343–7.PubMedGoogle Scholar
  102. 102.
    Haraguchi M, Furukawa T, Sumizawa T, Akiyama S. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res 1993; 53: 5680–2.PubMedGoogle Scholar
  103. 103.
    Harvey BG, Hackett NR, El-Sawy T et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 1999; 73: 6729–42.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Harvey BG, Hackett NR, Ely S, Crystal RG. Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals. Mol Ther 2001; 3: 206–15.PubMedGoogle Scholar
  105. 105.
    Harvey BG, Maroni J, O’Donoghue KA et al. Safety of local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13: 15–63.PubMedGoogle Scholar
  106. 106.
    Harvey BG, Worgall S, Ely S, Leopold PL, Crystal RG. Cellular immune responses of healthy individuals to intra-dermal administration of an E1–E3- adenovirus gene transfer vector. Hum Gene Ther 1999; 10: 2823–37.PubMedGoogle Scholar
  107. 107.
    Hasenburg A, Tong X-W, Rojas-Martinez A et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000; 7: 839–44.PubMedGoogle Scholar
  108. 108.
    Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res 2001; 61: 6377–81.PubMedGoogle Scholar
  109. 109.
    Hibino H, Tani K, Ikebuchi K et al. The common marmoset as a target preclinical primate model for cytokine and gene therapy studies. Blood 1999; 93: 2839–48.PubMedGoogle Scholar
  110. 110.
    Hortobagyi GN, Ueno NT, Xia W et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001; 19: 3422–33.PubMedGoogle Scholar
  111. 111.
    Huang M, Batra RK, Kogai T et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001; 8: 612–18.PubMedPubMedCentralGoogle Scholar
  112. 112.
    Huang Z, Waxman DJ. Modulation of cyclophosphamidebased cytochrome P450 gene therapy using liver P450 inhibitors. Cancer Gene Ther 2001; 8: 450–8.PubMedGoogle Scholar
  113. 113.
    Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 91: 8302–6.PubMedGoogle Scholar
  114. 114.
    Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J Biol Chem 1998; 273: 2322–8.PubMedGoogle Scholar
  115. 115.
    Ido A, Uto H, Moriuchi A et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human a-fetoprotein promoter. Cancer Res 2001; 61: 3016–21.PubMedGoogle Scholar
  116. 116.
    Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 2000; 6: 4422–31.PubMedGoogle Scholar
  117. 117.
    Inoue K, Wood CG, Slaton JW, Karashima T, Sweeney P, Dinney CP. Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncol Rep 2001; 8: 955–64.PubMedGoogle Scholar
  118. 118.
    Iyer M, Barrio JR, Namavari M et al. 8-[18F]fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET. J Nucl Med 2001; 42: 96–105.PubMedGoogle Scholar
  119. 119.
    Izawa JI, Sweeney P, Perrotte P et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 2002; 8: 1258–70.PubMedGoogle Scholar
  120. 120.
    Jacobs A, Tjuvajev JG, Dubrovin M et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001; 61: 2983–95.PubMedGoogle Scholar
  121. 121.
    Jansen M, Bardenheuer W, Sorg UR, Seeber S, Flasshove M, Moritz T. Protection of hematopoietic cells from O(6)- alkylation damage by O(6)- methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones. Eur J Haematol 2001; 67: 2–13.PubMedGoogle Scholar
  122. 122.
    Jiang A, Dornburg R. In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies. Gene Ther 1999; 6: 1982–7.PubMedGoogle Scholar
  123. 123.
    Kadowaki Y, Fujiwara T, Fukazawa T et al. Induction of differentiation-dependent apoptosis in human esophageal squamous cell carcinoma by adenovirus-mediated p21sdi1 gene transfer. Clin Cancer Res 1999; 5: 4233–41.PubMedGoogle Scholar
  124. 124.
    Kagawa S, Pearson SA, Ji L et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther 2000; 7: 75–9.PubMedGoogle Scholar
  125. 125.
    Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997; 15: 39–48.PubMedGoogle Scholar
  126. 126.
    Kaplan JM, Armentano D, Sparer TE et al. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum Gene Ther 1997; 8: 45–56.PubMedGoogle Scholar
  127. 127.
    Kasano K, Blackwell JL, Douglas JT et al. Selective gene delivery to head and neck cancer via an integrin targeted adenoviral vector. Clin Cancer Res 1999; 5: 2571–9.Google Scholar
  128. 128.
    Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33–40.PubMedGoogle Scholar
  129. 129.
    Kievit E, Bershad E, Ng E et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 1999; 59: 1417–21.PubMedGoogle Scholar
  130. 130.
    Kievit E, Nyati MK, Ng E et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 2000; 60: 6649–55.PubMedGoogle Scholar
  131. 131.
    Kim JH. 321–1999–06 A Phase I Study of E1B–Attenuated Replication Competent Adenovirus Vector–Mediated Intra–tumoral Administration of the E. coli Cytosine Deaminase/ HSV–1 Thymidine Kinase Fusion Gene in Conjunction with Two Prodrugs, 5–Fluorocytosine and Ganciclovir for Patients with Local Recurrence of Prostate Cancer after Radiation Therapy. Vol. 2002: National Institutes of Health Office of Biotechnology Activities Human Gene Transfer Clinical Trials Database, 1999.Google Scholar
  132. 132.
    Kirkman W III, Chen P, Schroeder R et al. Transduction and apoptosis induction in the rat prostate, using adenovirus vectors. Hum Gene Ther 2001; 12: 1499–512.PubMedGoogle Scholar
  133. 133.
    Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther 2001; 8: 89–98.Google Scholar
  134. 134.
    Kleinman HK, Liau G. Gene therapy for antiangiogenesis. J Natl Cancer Inst 2001; 93: 965–7.PubMedGoogle Scholar
  135. 135.
    Knox RJ, Jenkins TC, Hobbs SM, Chen S, Melton RG, Burke PJ. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res 2000; 60: 4179–86.PubMedGoogle Scholar
  136. 136.
    Kobune M, Xu Y, Baum C, Kelley MR, Williams DA. Retrovirus-mediated expression of the base excision repair proteins, formamidopyrimidine DNA glycosylase or human oxoguanine DNA glycosylase, protects hematopoietic cells from N,N’,N“- triethylenethiophosphoramide (thioTEPA)- induced toxicity in vitro and in vivo. Cancer Res 2001; 61: 5116–25.PubMedGoogle Scholar
  137. 137.
    Kojima A, Hackett NR, Ohwada A, Crystal RG. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest 1998; 101: 1789–96.PubMedPubMedCentralGoogle Scholar
  138. 138.
    Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998; 90: 273–86.PubMedGoogle Scholar
  139. 139.
    Kouraklis G. Gene therapy for cancer: from the laboratory to the patient. Dig Dis Sci 2000; 45: 1045–52.PubMedGoogle Scholar
  140. 140.
    Kramer K, Cheung NK. Antibody-based diagnostic and therapeutic innovations for human cancer. Compr Ther 2001; 27: 183–94.PubMedGoogle Scholar
  141. 141.
    Krasnykh V, Dmitriev I, Gomez-Navarro J et al. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res 2000; 60: 6784–7.PubMedGoogle Scholar
  142. 142.
    Lemoine NR. Tumor-selective transcriptional targeting for cancer gene therapy. Cancer Gene Ther 2000; 7: 1207–8.Google Scholar
  143. 143.
    Lerondel S, Le Pape A, Sene C et al. Radioisotopic imaging allows optimization of adenovirus lung deposition for cystic fibrosis gene therapy. Hum Gene Ther 2001; 12: 1–11.PubMedGoogle Scholar
  144. 144.
    Letourneau S, Greenbaum M, Cournoyer D. Retrovirusmediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells. Hum Gene Ther 1996; 7: 831–40.PubMedGoogle Scholar
  145. 145.
    Li H, Griscelli F, Lindenmeyer F et al. Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum Gene Ther 1999; 10: 3045–53.PubMedGoogle Scholar
  146. 146.
    Li H, Lindenmeyer F, Grenet C et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther 2001; 12: 515–26.PubMedGoogle Scholar
  147. 147.
    Li JH, Lax SA, Kim J, Klamut H, Liu FF. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 607–16.PubMedGoogle Scholar
  148. 148.
    Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther 2000; 7: 31–4.PubMedGoogle Scholar
  149. 149.
    Li S, Xia X, Zhang X, Suen J. Regression of tumors by IFNalpha electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Ther 2002; 9: 390–7.PubMedGoogle Scholar
  150. 150.
    Li Z, Shanmugam N, Katayose D et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther 1997; 4: 113–17.PubMedGoogle Scholar
  151. 151.
    Liau G, Su EJ, Dixon KD. Clinical efforts to modulate angiogenesis in the adult: gene therapy versus conventional approaches. Drug Discov Today 2001; 6: 689–97.PubMedGoogle Scholar
  152. 152.
    Lin P, Buxton JA, Acheson A et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998; 95: 8829–34.PubMedGoogle Scholar
  153. 153.
    Lodish HF, Berk AJ, Zipursky LS. Molecular Cell Biology, 4th edn. New York: W.H. Freeman, 2000.Google Scholar
  154. 154.
    Lohr F, Hu K, Haroon Z et al.. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2000; 2: 195–203.PubMedGoogle Scholar
  155. 155.
    Lohr M, Bago ZT, Bergmeister H et al. Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. J Mol Med 1999; 77: 393–8.PubMedGoogle Scholar
  156. 156.
    Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996; 87: 1097–103.PubMedGoogle Scholar
  157. 157.
    Mahasreshti PJ, Navarro JG, Kataram M et al. Adenovirusmediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001; 7: 2057–66.PubMedGoogle Scholar
  158. 158.
    Manome Y, Wen PY, Dong Yet al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 1996; 2: 567–73.PubMedGoogle Scholar
  159. 159.
    Marais R, Spooner RA, Light Y, Martin J, Springer CJ. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res 1996; 56: 4735–42.PubMedGoogle Scholar
  160. 160.
    Marais R, Spooner RA, Stribbling SM, Light Y, Martin J, Springer CJ. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat Biotechnol 1997; 15: 1373–7.PubMedGoogle Scholar
  161. 161.
    Markert JM, Medlock MD, Rabkin SD et al. Conditionally-replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867–74.PubMedGoogle Scholar
  162. 162.
    Martinet O, Ermekova V, Qiao JQ et al. Immunomodulatory gene therapy with interleukin 12 and 4–1BB ligand: long-term remission of liver metastases in a mouse model. J Natl Cancer Inst 2000; 92: 931–6.PubMedGoogle Scholar
  163. 163.
    Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988; 10 Suppl 3: S490–4.Google Scholar
  164. 164.
    Maxwell IH, Cripe TP. Transcriptional targeting. Tumor Targeting 2000; 4: 189–209.Google Scholar
  165. 165.
    McIvor RS. Gene therapy of genetic diseases and cancer. Pediatr Transplant 1999; 3 (Suppl. 1): 116–21.PubMedGoogle Scholar
  166. 166.
    McLachlin JR, Eglitis MA, Ueda K et al.Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst 1990; 82: 1260–3.PubMedGoogle Scholar
  167. 167.
    Medicine, Journal of Gene. Gene therapy clinical trials database. http://www.wiley.co.uk/wileychi/genmed/ clinical
  168. 168.
    Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831–5.PubMedGoogle Scholar
  169. 169.
    Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991; 88: 547–51.PubMedGoogle Scholar
  170. 170.
    Miki K, Xu M, Gupta A et al. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res 2001; 61: 6805–10.PubMedGoogle Scholar
  171. 171.
    Miller CR, Bharara S, Chiz S, Buchsbaum DJ, Gillespie GY. Cytosine deaminase/5-fluorocytosine gene-directed enzyme/prodrug therapy for malignant gliomas. Neuro-oncology 2001; 3: 292.Google Scholar
  172. 172.
    Miller CR, Gustin AN, Buchsbaum DJ et al. Quantitation of cytosine deaminase mRNA by real time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity in vitro. Anal Biochem 2002; 301: 189–99.PubMedGoogle Scholar
  173. 173.
    Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 2002; 62: 773–80.PubMedGoogle Scholar
  174. 174.
    Minaguchi T, Mori T, Kanamori Y et al. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res 1999; 59: 6063–7.PubMedGoogle Scholar
  175. 175.
    Misra V, Klamut HJ, Rauth AM. Expression of the prodrug-activating enzyme DT-diaphorase via Ad5 delivery to human colon carcinoma cells in vitro. Cancer Gene Ther 2002; 9: 209–17.PubMedGoogle Scholar
  176. 176.
    Moolten F. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276–81.PubMedGoogle Scholar
  177. 177.
    Moolten FL. Gene therapy: creating mosaic pattern of drug susceptibility. Mt Sinai J Med 1986; 53: 232.PubMedGoogle Scholar
  178. 178.
    Morita T, Matsuzaki A, Tokue A. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 2001; 92: 451–6.PubMedGoogle Scholar
  179. 179.
    Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 1992; 89: 33–7.PubMedGoogle Scholar
  180. 180.
    Multiple. Adenoviral vector safety and toxicity. Hum Gene Ther (Special Issue) 2002; 13: 1–175.Google Scholar
  181. 181.
    Nagata T, Nakamori M, Iwahashi M, Yamaue H. Over-expression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5’-deoxy-5-fluorouridine in tumour cells in vitro and in vivo. Eur J Cancer 2002; 38: 712–17.PubMedGoogle Scholar
  182. 182.
    Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001; 61: 8743–50.PubMedGoogle Scholar
  183. 183.
    Nemunaitis J, Swisher SG, Timmons T et al. Adenovirusmediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18: 609–22.PubMedGoogle Scholar
  184. 184.
    Niculescu-Duvaz I, Friedlos F, Niculescu-Duvaz D, Davies L, Springer CJ. Prodrugs for antibody-and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Anticancer Drug Des 1999; 14: 517–38.PubMedGoogle Scholar
  185. 185.
    Niculescu-Duvaz I, Niculescu-Duvaz D, Friedlos F et al. Self-immolative anthracycline prodrugs for suicide gene therapy. J Med Chem 1999; 42: 2485–9.PubMedGoogle Scholar
  186. 186.
    Nielsen LL, Maneval DC. P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52–63.PubMedGoogle Scholar
  187. 187.
    Niranjan A, Moriuchi S, Lunsford LD et al. Effective treatment of experimental glioblastoma by HSV vector-mediated TNFa and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2000; 2: 114–20.PubMedGoogle Scholar
  188. 188.
    Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001; 12: 861–70.PubMedGoogle Scholar
  189. 189.
    O’Shaughnessy JA, Cowan KH, Nienhuis AW et al. Retro-viral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 1994; 5: 891–911.PubMedGoogle Scholar
  190. 190.
    Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4: 39–69.PubMedGoogle Scholar
  191. 191.
    Pandha HS, Martin L-A, Rigg A et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999; 17: 2180–9.PubMedGoogle Scholar
  192. 192.
    Parker WB, Allan PW, Shaddix SC et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 1998; 55: 1673–81.PubMedGoogle Scholar
  193. 193.
    Parker WB, King SA, Allan PW et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 1997; 8: 1637–44.Google Scholar
  194. 194.
    Parsels LA, Kowalski MP, Wagner LM, Parsels JD, Maley F, Maybaum J. Escherichia coli thymidylate synthase expression protects human cells from the cytotoxic effects of 5- fluorodeoxyuridine more effectively than human thymidylate synthase overexpression. Cancer Gene Ther 2000; 7: 1179–87.PubMedGoogle Scholar
  195. 195.
    Pataer A, Fang B, Yu R et al. Adenoviral bak overexpression mediates caspase-dependent tumor killing. Cancer Res 2000; 60: 788–92.PubMedGoogle Scholar
  196. 196.
    Pataer A, Smythe WR, Yu R et al. Adenovirus-mediated bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg 2001; 121: 61–7.PubMedGoogle Scholar
  197. 197.
    Patel DH, Allay JA, Belt JA, Sorrentino BP. Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells. Blood 2000; 95: 2356–63.PubMedGoogle Scholar
  198. 198.
    Pawliuk R, Bachelot T, Zurkiya O, Eriksson A, Cao Y, Leboulch P. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol Ther 2002; 5: 345–51.PubMedGoogle Scholar
  199. 199.
    Pederson LC, Buchsbaum DJ, Vickers SM et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res 1997; 57: 4325–32.PubMedGoogle Scholar
  200. 200.
    Pederson LC, Vickers SM, Buchsbaum DJ et al. Combining cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells. J Gastrointest Surg 1998; 2: 283–91.PubMedGoogle Scholar
  201. 201.
    Pellicer A, Wigler M, Axel R, Silverstein S. The transfer and stable integration of the HSV thymidine kinase gene into mouse cells. Cell 1978; 14: 133–41.PubMedGoogle Scholar
  202. 202.
    RAID Project 404, Preclinical development of a tropism-modified adenoviral vector. National Cancer Institute, Developmental Therapeutics Program, Biological Resources Branch, Bethesda 2001.Google Scholar
  203. 203.
    Pfeifer A, Kessler T, Yang M et al. Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. Mol Ther 2001; 3: 319–22.PubMedGoogle Scholar
  204. 204.
    Piche A, Grim J, Rancourt C, Gomez-Navarro J, Reed JC, Curiel DT. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 1998; 58: 2134–40.PubMedGoogle Scholar
  205. 205.
    Podsakoff GM. Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector. Mol Ther 2001; 4: 282–3.PubMedGoogle Scholar
  206. 206.
    Ponnazhagan S, Curiel DT, Shaw DR, Alvarez RD, Siegal GP. Adeno-associated virus for cancer gene therapy. Cancer Res 2001; 61: 6313–21.PubMedGoogle Scholar
  207. 207.
    Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389–401.PubMedGoogle Scholar
  208. 208.
    Rainov NG, Dobberstein KU, Sena-Esteves M et al. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther 1998; 9: 1261–73.PubMedGoogle Scholar
  209. 209.
    Ram Z, Culver KW, Oshiro EM et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3: 1354–61.PubMedGoogle Scholar
  210. 210.
    Ramesh R, Saeki T, Templeton NS et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 2001; 3: 337–50.PubMedGoogle Scholar
  211. 211.
    Rancourt C, Rogers BE, Sosnowski BA et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998; 4: 2455–61.PubMedGoogle Scholar
  212. 212.
    Regulier E, Paul S, Marigliano M et al. Adenovirusmediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther 2001; 8: 45–54.PubMedGoogle Scholar
  213. 213.
    Riggs CE. Antitumor antibiotics and related compounds. In: Perry MC, ed. The Chemotherapy Source Book. Philadelphia: Lippincott Williams and Wilkins, 2001: 227–52.Google Scholar
  214. 214.
    Rödicker F, Stiewe T, Zimmermann S, Pützer BM. Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res 2001; 61: 7052–5.PubMedGoogle Scholar
  215. 215.
    Rogers BE, Chaudhuri TR, Belousova N et al. Evaluation of a dual gene adenovirus encoding somatostatin receptor subtype 2 and cytosine deaminase in the context of human prostate cancer. Proc Am Assoc Cancer Res 2002; 43: 84.Google Scholar
  216. 216.
    Rogers BE, Zinn KR, Buchsbaum DJ. Gene transfer strategies for improving radiolabeled peptide imaging and therapy. Q J Nucl Med 2000; 44: 208–23.PubMedGoogle Scholar
  217. 217.
    Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997; 8: 73–85.PubMedGoogle Scholar
  218. 218.
    Rosenberg SA, Aebersold P, Cornetta K et al. Gene transfer into humans–immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570–578.PubMedGoogle Scholar
  219. 219.
    Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997; 89: 21–39.PubMedGoogle Scholar
  220. 220.
    Roth JA, Molldrem J, Smythe WR. The current status of cancer gene therapy trials. PPO Updates: Prin Prac Oncol 1999; 13: 1–15.Google Scholar
  221. 221.
    Roth JA, Swisher SG, Merritt JA et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 1998; 25: 33–7.PubMedGoogle Scholar
  222. 222.
    Rowinsky EK, Tolcher AW. Topoisomerase I-targeting drugs. In: Perry MC, ed. The Chemotherapy Source Book. Philadelphia: Lippincott Williams and Wilkins, 2001: 289–304.Google Scholar
  223. 223.
    Saleh M, Jonas NK, Wiegmans A, Stylli SS. The treatment of established intracranial tumors by in situ retroviral IFNgamma transfer. Gene Ther 2000; 7: 1715–24.PubMedGoogle Scholar
  224. 224.
    Saleh M, Wiegmans A, Malone Q, Stylli SS, Kaye AH. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J Natl Cancer Inst 1999; 91: 438–45.PubMedGoogle Scholar
  225. 225.
    Sauerbrey A, McPherson JP, Zhao SC, Banerjee D, Bertino JR. Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside. Hum Gene Ther 1999; 10: 2495–504.PubMedGoogle Scholar
  226. 226.
    Scappaticci FA, Smith R, Pathak A et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther 2001; 3: 186–96.PubMedGoogle Scholar
  227. 227.
    Schellingerhout D, Bogdanov A Jr, Marecos E, Spear M, Breakefield X, Weissleder R. Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 1998; 9: 1543–9.PubMedGoogle Scholar
  228. 228.
    Schuler M, Herrmann R, De Greve JLP et al. Adenovirusmediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19: 1750–8.PubMedGoogle Scholar
  229. 229.
    Scott AM, Welt S. Antibody-based immunological therapies. Curr Opin Immunol 1997; 9: 717–22.PubMedGoogle Scholar
  230. 230.
    Secrist JA III, Parker WB, Allan PW et al. Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleosides Nucleotides 1999; 18: 745–57.Google Scholar
  231. 231.
    Seisenberger G, Ried MU, Endress T, Buning H, Hallek M, Brauchle C. Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 2001; 294: 1929–32.PubMedGoogle Scholar
  232. 232.
    Senter PD, Saulnier MG, Schreiber GJ et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 1988; 85: 4842–6.PubMedGoogle Scholar
  233. 233.
    Skibber JM, Minsky BD, Hoff PM. Cancer of the colon. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins, 2001: 1216–70.Google Scholar
  234. 234.
    Sorscher EJ, Peng S, Bebok Z et al. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994; 1: 233–8.PubMedGoogle Scholar
  235. 235.
    Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 1994; 20: 11–49.PubMedGoogle Scholar
  236. 236.
    Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP. A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 1996; 87: 2579–87.PubMedGoogle Scholar
  237. 237.
    Spitzweg C, O’Connor MK, Bergert ER, Tindall DJ, Young CYF, Morris JC. Treatment of prostate cancer by radio-iodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000; 60: 6526–30.PubMedGoogle Scholar
  238. 238.
    Spooner RA, Martin J, Friedlos F, Marais R, Springer CJ. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther 2000; 7: 1348–56.PubMedGoogle Scholar
  239. 239.
    Spooner RA, Maycroft KA, Paterson H, Friedlos F, Springer CJ, Marais R. Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy. Int J Cancer 2001; 93: 123–30.PubMedGoogle Scholar
  240. 240.
    Springer CJ, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest 2000; 105: 1161–7.PubMedPubMedCentralGoogle Scholar
  241. 241.
    Stackhouse MA, Buchsbaum DJ, Grizzle WE et al. Radio-sensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. Int J Radiat Oncol Biol Phys 1998; 42: 817–22.PubMedGoogle Scholar
  242. 242.
    Stackhouse MA, Pederson LC, Grizzle WE et al. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther 2000; 7: 1019–26.PubMedGoogle Scholar
  243. 243.
    Stegman LD, Rehemtulla A, Beattie B et al.Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1999; 96: 9821–6.PubMedGoogle Scholar
  244. 244.
    Sterman DH, Treat J, Litzky LA et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9: 1083–92.PubMedGoogle Scholar
  245. 245.
    Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000; 60: 4251–5.PubMedGoogle Scholar
  246. 246.
    Streit M, Stephen AE, Hawighorst T et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin2 using cell-based antiangiogenic gene therapy. Cancer Res 2002; 62: 2004–12.PubMedGoogle Scholar
  247. 247.
    Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120–6.PubMedGoogle Scholar
  248. 248.
    Suzuki S, Tadakuma T, Asano T, Hayakawa M. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations. Cancer Res 2001; 61: 1276–9.PubMedGoogle Scholar
  249. 249.
    Takebe N, Zhao SC, Ural AU et al. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther 2001; 8: 966–73.PubMedGoogle Scholar
  250. 250.
    Tepper JE. Combined radiotherapy and chemotherapy in the treatment of gastrointestinal malignancies. Semin Oncol 1992; 19: 96–101.PubMedGoogle Scholar
  251. 251.
    Thatcher NJ, Edwards RJ, Lemoine NR, Doehmer J, Davies DS. The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy. Cancer Gene Ther 2000; 7: 521–5.PubMedGoogle Scholar
  252. 252.
    Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes JP, Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998; 167: 41–9.Google Scholar
  253. 253.
    Tjuvajev JG, Chen SH, Joshi A et al. Imaging adenoviralmediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res 1999; 59: 5186–93.PubMedGoogle Scholar
  254. 254.
    Todo T, Feigenbaum F, Rabkin SD et al. Viral shedding and biodistribution of G207, a mutimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in Aotus. Mol Ther 2000; 2: 588–95.PubMedGoogle Scholar
  255. 255.
    Topf N, Worgall S, Hackett NR, Crystal RG. Regional ‘pro-drug’ gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther 1998; 5: 507–13.Google Scholar
  256. 256.
    Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999; 10: 3013–29.PubMedGoogle Scholar
  257. 257.
    Tran PL, Weinbach J, Opolon P et al. Prevention of bleomycin-induced pulmonary fibrosis after adenovirusmediated transfer of the bacterial bleomycin resistance gene. J Clin Invest 1997; 99: 608–17.PubMedPubMedCentralGoogle Scholar
  258. 258.
    Trepel M, Grifman M, Weitzman MD, Pasqualini R. Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum Gene Ther 2000; 11: 1971–81.PubMedGoogle Scholar
  259. 259.
    Ueno NT, Bartholomeusz C, Herrmann JL et al. E1Amediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000; 6: 250–9.PubMedGoogle Scholar
  260. 260.
    Valery CA, Seilhean D, Boyer O et al. Long-term survival after gene therapy for a recurrent glioblastoma. Neurology 2002; 58: 1109–12.PubMedGoogle Scholar
  261. 261.
    Van Rompay AR, Johansson M, Karlsson A. Phosphorylation of deoxycytidine analog monophosphates by UMPCMP kinase: molecular characterization of the human enzyme. Mol Pharmacol 1999; 56: 562–9.PubMedGoogle Scholar
  262. 262.
    Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses. Gene Ther 2000; 7: 2–8.PubMedGoogle Scholar
  263. 263.
    Viret C, Lindemann A. Tumor immunotherapy by vaccination with cytokine gene transfected cells. Int Rev Immunol 1997; 14: 193–212.PubMedGoogle Scholar
  264. 264.
    Waibel R, Alberto R, Willuda J et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 1999; 17: 897–901.PubMedGoogle Scholar
  265. 265.
    Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999; 10: 2237–43.PubMedGoogle Scholar
  266. 266.
    Wang G, Weiss C, Sheng P, Bresnick E. Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem Pharmacol 1996; 51: 1221–8.PubMedGoogle Scholar
  267. 267.
    Wei MX, Tamiya T, Chase M et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Human Gene Ther 1994; 5: 969–78.Google Scholar
  268. 268.
    Weinberg RA. How cancer arises. Sci Am 1996; 275: 62–70.PubMedGoogle Scholar
  269. 269.
    Wen XY, Bai Y, Stewart AK. Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. Hum Gene Ther 2001; 12: 347–58.PubMedGoogle Scholar
  270. 270.
    Weyel D, Sedlacek HH, Muller R, Brusselbach S. Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther 2000; 7: 224–31.PubMedGoogle Scholar
  271. 271.
    Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC, Potter PM. Sensitization of human tumor cells to CPT- 11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 2001; 61: 5078–82.PubMedGoogle Scholar
  272. 272.
    Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37–44.PubMedGoogle Scholar
  273. 273.
    Worth LL, Jia S-F, Zhou Z, Chen L, Kleinerman ES. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res 2000; 6: 3713–8.PubMedGoogle Scholar
  274. 274.
    Wu K, Eng E, Knox R, Chen S. Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model. Arch Biochem Biophys 2001; 385: 203–8.PubMedGoogle Scholar
  275. 275.
    Xiang J, Gomez-Navarro J, Arafat W et al. Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer. J Gene Med 2000; 2: 97–106.PubMedGoogle Scholar
  276. 276.
    Xie X, Zhao X, Liu Y et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001; 61: 6795–804.PubMedGoogle Scholar
  277. 277.
    Xu L, Pirollo KF, Tang W-H, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck xenografts. Hum Gene Ther 1999; 10: 2941–52.PubMedGoogle Scholar
  278. 278.
    Xu M, Kumar D, Stass SA, Mixson AJ. Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo. Mol Genet Metab 1998; 63: 103–9.PubMedGoogle Scholar
  279. 279.
    Xu Y, Hansen WK, Rosenquist TA, Williams DA, Limp-Foster M, Kelley MR. Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N’-bis(2- chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications. J Pharmacol Exp Ther 2001; 296: 825–31.PubMedGoogle Scholar
  280. 280.
    Yamabe K, Shimizu S, Ito T et al. Cancer gene therapy using a pro-apoptotic gene, caspase-3. Gene Ther 1999; 6: 1952–9.PubMedGoogle Scholar
  281. 281.
    Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the cyclooxyygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001; 3: 385–94.PubMedGoogle Scholar
  282. 282.
    Yoo GH, Hung M-C, Lopez-Berestein Get al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001; 7: 1237–45.PubMedGoogle Scholar
  283. 283.
    Young A, Kerr DJ. Genetic and immunological therapy for cancer. J R Soc Med 2000; 93: 10–14.PubMedPubMedCentralGoogle Scholar
  284. 284.
    Zheng X, Johansson M, Karlsson A. Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. J Biol Chem 2000; 275: 39125–9.PubMedGoogle Scholar
  285. 285.
    Zhou Z, Zwelling LA, Kawakami Y et al. Adenovirusmediated human topoisomerase Ha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 1999; 59: 4618–24.PubMedGoogle Scholar
  286. 286.
    Zhu C, Johansson M, Permert J, Karlsson A. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines. J Biol Chem 1998; 273: 14707–11.PubMedGoogle Scholar
  287. 287.
    Zinn KR, Buchsbaum DJ, Chaudhuri T, Mountz JM, Kirkman RL, Rogers BE. Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high affinity peptide radiolabeled with 99mTc or 188Re. J Nucl Med 2000; 41: 887–95.PubMedGoogle Scholar
  288. 288.
    Zinn KR, Chaudhuri TR, Belousova N et al. In vitro and in vivo imaging of99mTc-labeled recombinant adenovirus. Mol Ther 2002; (In Press).Google Scholar
  289. 289.
    Zinn KR, Chaudhuri TR, Buchsbaum DJ, Mountz JM, Rogers BE. Detection and measurement of in vitro gene transfer by gamma camera imaging. Gene Ther 2001; 8: 291–9.PubMedGoogle Scholar
  290. 290.
    Zinn KR, Chaudhuri TR, Buchsbaum DJ, Mountz JM, Rogers BE. Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging. Nucl Med Biol 2001; 28: 135–44.PubMedGoogle Scholar
  291. 291.
    Zinn KR, Chaudhuri TR, Krasnykh VN et al. Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus. Radiology 2002; 223: 417–25.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • Donald J. Buchsbaum
  • C. Ryan Miller
  • Parameshwar J. Mahasreshti
  • David T. Curiel

There are no affiliations available

Personalised recommendations